Jeffrey Sosman, MD
Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine
I am a clinical investigator vested in the immune-based and targeted therapy of melanoma. I have played a role in the clinical development of the immune checkpoint inhibitors. I am involved in efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance. I have developed an expanding interest metastatic disease to brain. Understanding and manipulating the tumor microenvironment is a major avenue to enhance the effects of immune checkpoint inhibitors. More recently I have also turned to focus on ICP induced toxicity (autoimmunity) and understanding their mechanisms. The Translational Research in Solid Tumors (TRIST) program in the Cancer Center. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers and am working to bring translational studies to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority.